Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (47)

« Back to Publications

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

Ding J. et al, (2026), British Journal of Clinical Pharmacology, 92, 589 - 605

Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)

Assmus F. et al, (2025), PLOS Neglected Tropical Diseases, 19, e0013522 - e0013522

Pharmacometric and statistical considerations for dose optimization

Chotsiri P. et al, (2025), CPT: Pharmacometrics & Systems Pharmacology, 14, 279 - 291

Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants

Wattanakul T. et al, (2024), Nature Communications, 15

Medication adherence framework: A population‐based pharmacokinetic approach and its application in antimalarial treatment assessments

Ding J. et al, (2024), CPT: Pharmacometrics & Systems Pharmacology, 13, 795 - 811

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study

Flower B. et al, (2023), eLife, 12

Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 112, 824 - 835

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

Assmus F. et al, (2022), Microorganisms, 10, 1639 - 1639

A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics

Wattanakul T. et al, (2022), Expert Review of Clinical Pharmacology, 15, 945 - 958

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Driouich J-S. et al, (2022), eBioMedicine, 82, 104148 - 104148

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Peto TJ. et al, (2022), The Lancet Infectious Diseases, 22, 867 - 878

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside

Assmus F. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010219 - e0010219

Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 111, 676 - 685

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

Abdelnabi R. et al, (2022), Nature Communications, 13

Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria

Taylor WR. et al, (2021), Malaria Journal, 20

Load More